Auden McKenzie
Committed to providing quality pharmaceutical products and currently holds over 70 product.
| GBP | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Auden McKenzie, established in 2001, operates as a pharmaceutical company focused on the development and licensing of niche generic medicines. The firm was founded by Amit Patel. Patel, a pharmacist by training, embarked on his entrepreneurial journey after gaining experience in his father's pharmacy and working at a major pharmaceutical wholesaler, giving him deep insight into the industry's supply chain and product opportunities. This background enabled him to identify and capitalize on overlooked or complex-to-manufacture generic drugs.
The company's core business involves acquiring or in-licensing marketing authorisations for established pharmaceutical products and managing the entire supply chain, from manufacturing to distribution. Auden McKenzie serves the National Health Service (NHS) and the Irish Health Service Executive (HSE), along with pharmaceutical wholesalers and pharmacies across the United Kingdom and Europe. Its revenue is generated from the sale of these licensed pharmaceutical products. The product portfolio consists of a wide range of medicines in various forms, including tablets, capsules, liquids, and injectables, covering diverse therapeutic areas. A key aspect of Auden McKenzie's strategy is its asset-light model; the company does not engage in its own research and development or manufacturing, instead partnering with third-party manufacturers.
In a significant milestone, the company was acquired by Accord Healthcare, a subsidiary of Intas Pharmaceuticals, in 2017. This acquisition was a strategic move for Accord to strengthen its position in the UK and European markets by integrating Auden McKenzie's established portfolio and commercial infrastructure. Prior to the acquisition, Auden McKenzie had demonstrated substantial growth, recognized by its inclusion in the Sunday Times Fast Track 100 list of the UK's fastest-growing private companies.
Keywords: generic pharmaceuticals, pharmaceutical licensing, healthcare, supply chain management, NHS supplier, European markets, niche medicines, pharmaceutical distribution, Accord Healthcare, Intas Pharmaceuticals